Denali Therapeutics Inc. (NasdaqGS: DNLI)
Health Care · Biotechnology · US
$19.09
-1.85% today · +20.3% 1Y
Denali Therapeutics Inc. (NasdaqGS: DNLI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.11B and employs 503 people.
Over the last twelve months the share price has gained 20.3%, trading between 13.75 and 27.30.
Tweenvest scores Denali Therapeutics Inc. across four factors: quality 38/100, value 44/100. Its strongest factor is value.
DNLI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.11B
- Revenue (TTM)
- $3.60M
- P/E
- —
- EPS
- -2.83
- Dividend yield
- —
- Beta (5Y)
- 1.02
- 52-week high
- $27.30
- 52-week low
- $13.75
- Avg volume (3M)
- —
- Shares outstanding
- 159.85M
- Employees
- 503
- Next earnings
- —
About Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
- ISIN
- US24823R1059
- Founded
- 2013
- Listed since
- Dec 8, 2017
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.NasdaqGS: ARQT | $3.34B | $26.43 | -0.56% |
| Viking Therapeutics, Inc.NasdaqCM: VKTX | $3.33B | $28.43 | -0.28% |
| Celcuity Inc.NasdaqCM: CELC | $3.32B | $65.81 | -3.14% |
| CareDx, Inc.NasdaqGM: CDNA | $3.29B | $61.73 | -3.05% |
| Arcus Biosciences, Inc.NYSE: RCUS | $3.11B | $24.53 | +0.49% |
| Dyne Therapeutics, Inc.NasdaqGS: DYN | $3.11B | $16.15 | -2.94% |
| Acrobiosystems Co.,Ltd.SZSE: 301080 | $3.06B | CN¥122.20 | -13.38% |
| Xiamen Amoytop Biotech Co., Ltd.SHSE: 688278 | $3.01B | CN¥50.77 | -4.01% |
Figures last refreshed Oct 11, 2026.